Evidence map›Paper›PMID 34427856›Full record

ArticleGeroScience2021

Reversal of deficits in aged skeletal muscle during disuse and recovery in response to treatment with a secrotome product derived from partially differentiated human pluripotent stem cells.

Dennis K Fix, Ziad S Mahmassani, Jonathan J Petrocelli, Naomi M M P de Hart, Patrick J Ferrara, Jessie S Painter, Gabriel Nistor, Thomas E Lane, Hans S Keirstead, Micah J Drummond

Open access · hybridAbstract read
In one paragraph

Article in GeroScience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Dennis K FixDepartment of Physical Therapy and Athletic Training, University of Utah, 520 Wakara Way, UT, 84108, Salt Lake City, USA.
Ziad S MahmassaniDepartment of Physical Therapy and Athletic Training, University of Utah, 520 Wakara Way, UT, 84108, Salt Lake City, USA.
Jonathan J PetrocelliDepartment of Physical Therapy and Athletic Training, University of Utah, 520 Wakara Way, UT, 84108, Salt Lake City, USA.
Naomi M M P de HartDepartment of Nutrition and Integrative Physiology, University of Utah, UT, Salt Lake City, USA.
Patrick J FerraraDepartment of Physical Therapy and Athletic Training, University of Utah, 520 Wakara Way, UT, 84108, Salt Lake City, USA.
Jessie S PainterImmunis, Inc, Irvine, CA, USA.
Gabriel NistorImmunis, Inc, Irvine, CA, USA.
Thomas E LaneDepartment of Neurobiology and Behavior, University of California, Irvine, CA, USA.
Hans S KeirsteadImmunis, Inc, Irvine, CA, USA.
Micah J DrummondDepartment of Physical Therapy and Athletic Training, University of Utah, 520 Wakara Way, UT, 84108, Salt Lake City, USA.
University of Utah · USUniversity of California, Irvine · US

Funding

LOOH-induced muscle atrophy with ageR01AG074535 · NIA · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Micah J Drummond, Katsuhiko Funai · 2022 to 2026
$3.0M
Novel molecular mechanisms of skeletal muscle insulin resistance in physically inactive older adultsR01AG050781 · NIA · UNIVERSITY OF UTAH · PI DRUMMOND, MICAH J · 2016 to 2020
$1.7M
NIA NIH HHS R01 AG050781NIA NIH HHS R01 AG074535
6 · The paper itself

Abstract

Aged individuals are at risk to experience slow and incomplete muscle recovery following periods of disuse atrophy. While several therapies have been employed to mitigate muscle mass loss during disuse and improve recovery, few have proven effective at both. Therefore, the purpose of this study was to examine the effectiveness of a uniquely developed secretome product (STEM) on aged skeletal muscle mass and function during disuse and recovery. Aged (22 months) male C57BL/6 were divided into PBS or STEM treatment (n = 30). Mice within each treatment were assigned to either ambulatory control (CON; 14 days of normal cage ambulation), 14 days of hindlimb unloading (HU), or 14 days of hindlimb unloading followed by 7 days of recovery (recovery). Mice were given an intramuscular delivery into the hindlimb muscle of either PBS or STEM every other day for the duration of their respective treatment group. We found that STEM-treated mice compared to PBS had greater soleus muscle mass, fiber cross-sectional area (CSA), and grip strength during CON and recovery experimental conditions and less muscle atrophy and weakness during HU. Muscle CD68 +, CD11b + and CD163 + macrophages were more abundant in STEM-treated CON mice compared to PBS, while only CD68 + and CD11b + macrophages were more abundant during HU and recovery conditions with STEM treatment. Moreover, STEM-treated mice had lower collagen IV and higher Pax7 + cell content compared to PBS across all experimental conditions. As a follow-up to examine the cell autonomous role of STEM on muscle, C2C12 myotubes were given STEM or horse serum media to examine myotube fusion/size and effects on muscle transcriptional networks. STEM-treated C2C12 myotubes were larger and had a higher fusion index and were related to elevated expression of transcripts associated with extracellular matrix remodeling. Our results demonstrate that STEM is a unique cocktail that possesses potent immunomodulatory and cytoskeletal remodeling properties that may have translational potential to improve skeletal muscle across a variety of conditions that adversely effect aging muscle.

Indexed as

Pluripotent Stem CellsSecretomeAnimalsHumansMaleMiceMice, Inbred C57BLMuscle, SkeletalMuscular AtrophyAtrophyFibrosisImmune cellsInflammationSarcopeniaStem cells

Identifiers

PMID34427856
PMCPMC8602548
OpenAlexW3195801356

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.